Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

6.905 -0.035 (-0.50%)
Streaming Delayed Price Updated: 12:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week
The cancer-focused biotech has a bright future, according to one pundit. 
Via The Motley Fool
Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Relay (RLAY) Q2 Loss Narrows 41%
Via The Motley Fool
Topics Intellectual Property
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Preview: Relay Therapeutics's Earnings
 
Via Benzinga
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering. 
Via Benzinga
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
Why Relay Therapeutics Plummeted by Nearly 14% Today
Investors weren't happy with the company's latest effort at capital-raising. 
Via The Motley Fool
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
 
Via Benzinga
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Expert Ratings For Relay Therapeutics
 
Via Benzinga
Expert Ratings For Relay Therapeutics
 
Via Benzinga
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns... 
Via Benzinga
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
Dow Jumps Over 1% Following Last Week's Selloff: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone
 
Via Benzinga
Topics Stocks
Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher
 
Via Benzinga
Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July
 
Via Benzinga
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics,... 
Via Benzinga
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
US Stocks Higher; Dow Surges Over 200 Points
 
Via Benzinga
Topics Stocks
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS for Q2 2024
RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
This article identifies the 
Via Talk Markets
Topics Artificial Intelligence
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.